Intarcia Therapeutics, Inc. and Quintiles, Inc. Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

HAYWARD, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--To speed development of a potential ground-breaking therapy for Type 2 diabetes – a debilitating and deadly disease that currently affects almost 350 million people worldwide – Intarcia Therapeutics, Inc., and Quintiles today announced the signing of definitive agreements whereby Quintiles will become a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).

Back to news